| abstract |
Provided herein are novel anti-CLDN antibodies and antibody drug conjugates (ADC), including their derivatives, and methods of using them to treat proliferative disorders. In selected embodiments, the invention includes antibodies that bind to cancer stem cells that express at least one protein of the CLDN family. In another embodiment, the antibodies of the invention specifically bind to CLND6 or specifically bind to CLDN6 and CLDN9. In another embodiment, the antibodies of the invention bind to CLDN6 and CLDN9 with substantially the same apparent binding affinity. |